Clinical Trials Sponsored by Immunov

Total 362 results

IMMUNOe Research Centers

Unknown

Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Covid19 | Post-Viral Fatigue Syndrome | Post-Viral Disorder (Disorder)

United States
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
Bionor Immuno AS

Completed

Re-boosting of HIV-1 Infected Subjects With Vacc-4x (Re-boost)

HIV-1 Infection

United States, Spain, Germany, Italy, United Kingdom
Bionor Immuno AS

Completed

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

HIV I Infection

Germany, United States, Spain, United Kingdom, Italy
Bionor Immuno AS

Completed

Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART

HIV-1 Infection

Norway
Assistance Publique - Hôpitaux de Paris
Immunov

Terminated

Immunological Response to COVID-19 Vaccine in Patients With Autoimmune and Inflammatory Diseases Treated With Immunosuppressants and/or Biologics (COVADIS)

Autoimmune Diseases | Inflammatory Disorder

France
Imunon

Active, not recruiting

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (OVATION 2)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States, Canada
Imunon

Terminated

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) (ABLATE)

Colon Cancer Liver Metastasis

United States
Imunon

Not yet recruiting

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

SARS CoV 2 Infection

United States
Imunon

Completed

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA)

Hepatocellular Carcinoma

Korea, Republic of, China, Hong Kong, Singapore, Thailand, Malaysia, United States, Canada, Taiwan, Spain, Philippines, Germany, Italy, Vietnam
Imunon

Completed

Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States, Taiwan, Korea, Republic of, China, Italy, Hong Kong, Thailand, Canada, Malaysia, Japan, Philippines
Immunic AG

Active, not recruiting

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) (EMPhASIS)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Poland, Bulgaria, Romania, Ukraine
Immunovia, Inc.

Completed

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Pancreatic Ductal Adenocarcinoma | Familial Pancreatic Cancer | FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome

United States, Sweden, Canada, Spain, United Kingdom
Inmunova S.A.

Completed

A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.

Covid19

Argentina
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
IMMUNOe Research Centers
Octapharma

Unknown

A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) (PANS)

Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections | Pediatric Acute-Onset Neuropsychiatric Syndrome

United States
Imunon

Completed

Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Imunon

Withdrawn

Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients (EURO-DIGNITY)

Breast Cancer

Israel, Czechia, Italy
Imunon

Completed

A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

Liver Neoplasms | Hepatocellular Carcinoma

United States
Imunon

Completed

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall (DIGNITY)

Breast Cancer

United States
Immunis, Inc.

Recruiting

Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

Muscle Atrophy

United States
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Immunic AG

Active, not recruiting

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis (CALLIPER)

Multiple Sclerosis

Germany, United States, Netherlands, Bulgaria, Serbia, Canada, Czechia, Moldova, Republic of, North Macedonia, Poland, Romania, Ukraine
PrimeVax Immuno-Oncology Inc.

Not yet recruiting

Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma

Metastatic Melanoma
Assistance Publique - Hôpitaux de Paris
Fonds IMMUNOV

Completed

Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV) (AMBUCOV)

Covid19 | SARS-CoV-2

France
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-1)

Multiple Sclerosis

Spain, United States, India, Mexico, Bulgaria, Georgia, Lithuania, Moldova, Republic of, North Macedonia, Jordan, Greece, Albania, Colombia, Montenegro, Ukraine, Lebanon
Immunic AG

Terminated

Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (CALDOSE-1)

Ulcerative Colitis

United States, Russian Federation, Serbia, Belarus, Netherlands, Spain, United Kingdom, Croatia, Poland, Albania, Bosnia and Herzegovina, Bulgaria, Czechia, Georgia, North Macedonia, Portugal, Romania, Turkey, Ukraine
Immunic AG

Terminated

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United Kingdom
Immuron Ltd.

Terminated

Treatment for Clostridium-difficile Infection With IMM529

Clostridium Difficile Infection | Clostridium Difficile Infection Recurrence

Israel
Immuron Ltd.

Withdrawn

Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis
Immune Design

Terminated

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Melanoma | Sarcoma | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Immune Pharmaceuticals

Unknown

Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

Israel
Immune Control

Unknown

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Multiple Myeloma

United States
Inmunova S.A.
Exeltis

Terminated

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

Hemolytic-Uremic Syndrome | Pediatric Kidney Disease | Bloody Diarrhea | STEC, Unspecified

Argentina
Amgen
Immunex Corporation

Terminated

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials

Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders

Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis

Psoriasis | Psoriatic Arthritis
Amgen
Immunex Corporation

Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012

Rheumatoid Arthritis
Amgen
Immunex Corporation

Completed

Enbrel Liquid Immunogenicity Protocol

Rheumatoid Arthritis
Abgenix
Immunex Corporation

Completed

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

Prostate Cancer

United States
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Immune Design

Completed

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States
Immune Pharmaceuticals

Completed

Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid

Pemphigoid, Bullous

United States, Israel
Immune Design

Completed

A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer

Melanoma | Sarcoma | Breast Cancer | Ovarian Cancer | Non-small Cell Lung Cancer

United States
Bionor Immuno AS
Celgene Corporation

Completed

Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART) (IMID)

HIV-1 Infection

Germany
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
University of Miami
Immuno Laboratories

Completed

IgG-mediated Food Test for Weight Loss

Overweight and Obesity

United States

3

Subscribe